STAT May 8, 2024
Good morning. Today we ponder, how much will the advisory committee meeting for Lilly’s donanemab matter? Send me your thoughts, and as always, any ideas or tips: [email protected].
Young boy dies in Pfizer Duchenne trial
A young boy died in a trial for Pfizer’s experimental gene therapy for Duchenne muscular dystrophy, the company told patient advocates yesterday.
Pfizer said the boy, who was enrolled in a trial for boys ages 2 or 3, received the therapy last year and died of cardiac arrest, but that researchers had not yet determined precisely what happened or whether the death was linked to the treatment.
The company said it is pausing crossing over patients in a separate Phase 3 trial of the...
Today's Sponsors
Today's Sponsor